Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / BioStem Technologies Appoints New Directors
Business board appointment

BioStem Technologies Appoints New Directors

Analysis based on 6 articles · First reported Jun 09, 2026 · Last updated Jun 09, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The appointment of three new independent directors with diverse expertise is expected to positively impact BioStem Technologies' stock price and governance. This strategic move is aimed at scaling the business and working towards a Nasdaq uplisting, which could lead to increased investor confidence and market valuation for BioStem Technologies.

Biotechnology Healthcare Investment Management
Event Summary

BioStem Technologies Inc. announced the appointment of three new independent directors, Glicko rating system, Steven D. Sonenreich, and Rayna Lesser Hannaway, to its Board of Directors, effective June 5, 2026. These appointments are intended to strengthen the company's board with deep expertise in life sciences commercialization, healthcare administration, and investment management. Concurrently, Tom Dugan and Patrick Daly resigned from the board. The new directors will also serve on various committees, with Glicko rating system chairing the Compensation Committee, and Steven D. Sonenreich and Rayna Lesser Hannaway joining the Audit Committee and Corporate Governance and Nominating Committee. Chairman and CEO Jason Matuszewski highlighted that their collective insights will be invaluable for BioStem Technologies' next phase of growth, strengthening governance, and working towards a Nasdaq uplisting.

Key Actions
80 Glicko rating system appointed BioStem Technologies
80 Steven D. Sonenreich appointed BioStem Technologies
80 Rayna Lesser Hannaway appointed BioStem Technologies
70 BioStem Technologies appointed directors
20 Tom Dugan resigned BioStem Technologies
20 Patrick Daly resigned BioStem Technologies
Entities Involved
stock
BioStem Technologies
BioStem Technologies appointed three new independent directors to its Board of Directors, which is expected to strengthen its governance and aid in its goal of a Nasdaq uplisting. This move is seen as positive for the company's growth and strategic direction.
Importance 100 Sentiment 50
per
Glicko rating system
Glicko rating system was appointed to the Board of Directors of BioStem Technologies and as Chair of the Compensation Committee, bringing extensive experience in life sciences commercialization.
Importance 80 Sentiment 30
per
Steven D. Sonenreich
Steven D. Sonenreich was appointed to the Board of Directors of BioStem Technologies and as a member of the Audit Committee and Corporate Governance and Nominating Committee, contributing his expertise in healthcare administration.
Importance 80 Sentiment 30
per
Rayna Lesser Hannaway
Rayna Lesser Hannaway was appointed to the Board of Directors of BioStem Technologies and as a member of the Audit Committee and Corporate Governance and Nominating Committee, providing deep investment management experience.
Importance 80 Sentiment 30
per
Tom Dugan
Tom Dugan resigned from the Board of Directors of BioStem Technologies.
Importance 20 Sentiment 0
per
Patrick Daly
Patrick Daly resigned from the Board of Directors of BioStem Technologies.
Importance 20 Sentiment 0
per
Jason Matuszewski
Jason Matuszewski, Chairman and CEO of BioStem Technologies, expressed enthusiasm for the new board appointments.
Importance 10 Sentiment 0
ngo
BioFlorida
Glicko rating system is the President and CEO of BioFlorida.
Importance 10 Sentiment 0
oth
MetaVia
Glicko rating system serves on the Board of Directors of MetaVia.
Importance 5 Sentiment 0
priv
Otsuka Precision Health
Glicko rating system serves on the Board of Directors of Otsuka Precision Health.
Importance 5 Sentiment 0
stock
TherapeuticsMD
Glicko rating system previously served as Chief Executive Officer of TherapeuticsMD, Inc.
Importance 5 Sentiment 0
priv
Paragon Therapeutics
Glicko rating system was Chief Commercial Officer of Paragon Therapeutics.
Importance 5 Sentiment 0
priv
Mount Sinai Hospital
Steven D. Sonenreich led a successful financial turnaround and major capital campaigns at Mount Sinai Medical Center.
Importance 5 Sentiment 0
priv
Polen Capital
Rayna Lesser Hannaway most recently served as Head of the Small Company Growth Team and Portfolio Manager at Polen Capital.
Importance 5 Sentiment 0
priv
Fidelity Investments
Rayna Lesser Hannaway spent over a decade at Fidelity Investments as an analyst and portfolio manager.
Importance 5 Sentiment 0
+ 2 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.